Core Viewpoint - The company has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.00 yuan per 10 shares for all shareholders, totaling approximately 72.63 million yuan [3][4]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting held on April 18, 2025, and is based on a total share capital of 741,623,525 shares, excluding 15,275,701 shares held in the company's repurchase account and 14,100 shares subject to judicial freeze [3][4]. - The cash dividend of 1.00 yuan per 10 shares (before tax) will be distributed to shareholders, with a total cash distribution amounting to 72,633,372.40 yuan [3][4]. - The reference price for ex-dividend will be adjusted based on the closing price on the record date minus the cash dividend per share [4][6]. Group 2: Shareholder Rights and Exclusions - Shareholders holding shares in the repurchase account and those with shares subject to judicial freeze will not be entitled to participate in this profit distribution [5][6]. - The record date for the distribution is set for June 6, 2025, and the ex-dividend date is June 9, 2025 [5][6]. Group 3: Taxation and Dividend Payment - The cash dividends will be directly credited to shareholders' accounts through their custodial securities companies [5]. - Different tax rates will apply to various categories of shareholders, with specific provisions for foreign investors and domestic funds [4][6].

桂林莱茵生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 11 月 28 日召开 2024 年第二次临时股东会，会议审议通过了《关于回购 注销 2022 年限制性股票激励计划部分限制性股票的提案》，并于 2025 年 2 月 5 日完成了《2022 年限制性股票激励计划》中激励对象持有的已获授但尚未解除 限售的限制性股票共计 363,300 股的回购注销手续，剩余应被回购注销的 14,100 股限制性股票因激励对象个人原因被司法冻结，暂未办理完回购注销手续。该部 分尚未完成回购注销的 14,100 股股份不享有本次利润分配的权利。同时，公司 通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份数量为 15,275,701 股，该部分股份不享有股东会表决权、利润分配、公积金转增股本等 相关权利。 因此，公司 2024 年度利润分配方案为：以公司现有总股本 741,623,525 股扣 除公司回购专用证券账户中的 15,275,701 股及公司限 ...

Core Insights - The beer sector experienced a rise of 1.14%, ranking 7th among concept sectors, with 15 stocks increasing in value, led by Lehui International, Qingdao Beer, and Zhujiang Beer, which rose by 10.02%, 3.05%, and 3.05% respectively [1][2][3] - The sector saw a net inflow of 0.92 billion yuan, with 13 stocks receiving net inflows, and five stocks exceeding 10 million yuan in net inflow, with Lehui International leading at 392.99 million yuan [2][3] Sector Performance - The beer concept sector had a positive performance with notable gains from key players such as Lehui International, Qingdao Beer, and Chongqing Beer, while stocks like Jinzongzi and Zhuhai Zhongfu faced declines [1][2] - The top gainers in the beer sector included Lehui International with a 10.02% increase, followed by Qingdao Beer at 3.05% and Chongqing Beer at 2.64% [3][4] Fund Flow Analysis - Lehui International, *ST Lanhua, and Jinhui Wine had the highest net inflow ratios at 11.44%, 7.57%, and 6.64% respectively, indicating strong investor interest [3][4] - The main inflow of funds was concentrated in Lehui International, which attracted 392.99 million yuan, followed by Qingdao Beer and Chongqing Beer with inflows of 270.70 million yuan and 224.53 million yuan respectively [2][3]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [7] Core Viewpoints - The company is leveraging synthetic biology to enhance the production of plant extracts, addressing key technological challenges in scaling natural product production [1] - The dual technology strategy of "natural extraction + biosynthesis" has been elevated to a strategic goal, with significant progress in the biosynthesis of natural sweeteners and polysaccharides [2] - The company has achieved breakthroughs in natural sweeteners and functional polysaccharides, including the mass production capability of steviol glycosides and the full synthetic pathway for monk fruit sweetener [3][4] Summary by Sections Industry Overview - The plant extract industry in China entered a quality improvement phase in 2021, with technological innovations driving development [1] Company Developments - Since 2016, the company has collaborated with research institutions to develop biosynthesis technologies for natural sweeteners, resulting in the establishment of two R&D platforms [2] - The company has obtained 8 patents in synthetic biology and has a production capacity of over 1,000 tons annually, with an expected annual output value exceeding 1 billion yuan [2] Product Progress - The company has developed a high-value steviol glycoside, Reb M2, which is set to receive FDA GRAS certification by February 2025, allowing it to be marketed in the US [3] - The company is the first to achieve a fully synthetic pathway for monk fruit sweetener, addressing the limitations of natural sourcing [3] - A new functional polysaccharide, L-β-glucan, has been developed with various health benefits and is expected to receive FDA GRAS certification by 2025 [4] Financial Forecast & Investment Recommendations - The company has adjusted its revenue forecasts for 2025-2027 to 2.08 billion, 2.48 billion, and 2.99 billion yuan respectively, with net profits of 212.53 million, 288.09 million, and 395.93 million yuan [5] - The company is expected to maintain strong growth in the plant extraction and synthetic biology sectors, justifying the "Buy" rating [5]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [7]. Core Insights - The company is leveraging synthetic biology to enhance the production of plant extracts, addressing key technological challenges in scaling natural product production [1]. - The dual technology strategy of "natural extraction + biological synthesis" has been elevated to a strategic goal, with significant progress in the field of natural sweeteners and polysaccharides [2]. - The company has achieved breakthroughs in natural sweeteners, including the mass production capability of steviol glycosides and the full synthetic pathway for monk fruit sweetener [3][4]. Summary by Sections Section 1: Industry Development - The plant extract industry in China entered a quality improvement phase in 2021, with technological innovations driving growth and reducing dependency on raw materials [1]. Section 2: Company Strategy - Since 2016, the company has collaborated with research institutions to develop biological synthesis technologies for natural sweeteners, resulting in the establishment of two R&D platforms [2]. - The company has obtained 8 patents in synthetic biology and has a production capacity of over 1,000 tons annually, with an expected annual output value exceeding 1 billion yuan [2]. Section 3: Product Progress - The company has developed a high-value steviol glycoside, Reb M2, which is set to receive FDA GRAS certification by February 2025, allowing it to be marketed in the U.S. [3]. - The company is the first to successfully synthesize monk fruit sweetener, addressing the limitations of natural sourcing [3]. - A new functional polysaccharide, L-β-galactomannan, has been developed with various health benefits and is expected to receive FDA GRAS certification by 2025 [4]. - The company is actively researching ergothioneine, which has promising market potential [4]. Section 4: Financial Forecast & Investment Recommendations - The revenue forecast for 2025-2027 is adjusted to 2.08 billion, 2.48 billion, and 2.99 billion yuan, with net profits of 212.53 million, 288.09 million, and 395.93 million yuan respectively [5]. - The company is expected to see significant growth in the plant extraction and synthetic biology sectors, maintaining a "Buy" rating [5].

Market Overview - As of 13:59 today, the Shanghai Composite Index is at 3372.33 points, with a slight decline of -0.23% [1] - The total trading volume of A-shares today is 838.849 billion yuan [1] Stocks Breaking Annual Line - A total of 68 A-shares have surpassed their annual line today, with notable stocks including: - Puris (乖离率 6.48%) - Aisen Co., Ltd. (乖离率 5.81%) - Fosa Technology (乖离率 4.02%) [1] Stocks with Significant Deviation - The stocks with the largest deviation from the annual line include: - Puris: Today's price increased by 7.19% to 30.70 yuan - Aisen Co., Ltd.: Today's price increased by 7.47% to 42.00 yuan - Fosa Technology: Today's price increased by 4.30% to 32.71 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance and their respective deviations include: - Yao Stone Technology: 3.77% increase, 3.51% deviation - Fuling Power: 6.24% increase, 3.42% deviation - Yingjie Electric: 5.37% increase, 3.38% deviation [1] Summary of Stocks with Minor Deviations - Stocks with minor deviations from the annual line include: - Huayang Intelligent: 4.58% increase, 2.48% deviation - Boying Special Welding: 2.32% increase, 2.06% deviation - Stone Technology: 2.02% increase, 1.96% deviation [1]

Group 1 - Qingmu Technology plans to reduce its shareholding by up to 3%, amounting to no more than 2.776 million shares [1] - Newcap received a decision from the police to revoke the case against its actual controller, who was previously detained for insider trading [2] - Rhine Biotech's directors and executives plan to collectively reduce their holdings by up to 0.14%, totaling no more than 1.0185 million shares [3] Group 2 - Puli Tui's stock and convertible bonds will be delisted on May 22, 2025 [5] - *ST Nong Shang will have its delisting risk warning lifted and will resume trading on May 23, 2025 [7] - State Grid Information Communication plans to acquire 100% equity of Yili Technology for approximately 1.853 billion yuan [9] Group 3 - Kelun Pharmaceutical's subsidiary received drug registration approval for a new injectable product, which is the first of its kind in China [10] - Aishida plans to acquire 7% equity of its subsidiary Zhejiang Qianjiang Robot Co., Ltd. for 13.09 million yuan [11] - Hongming Co. is planning to acquire 83% equity of Shenzhen Chisu Automation Equipment Co., Ltd. for approximately 151 million yuan [12] Group 4 - JuJiao Co. plans to reduce its shareholding by up to 2.6%, totaling no more than 2.093 million shares [14] - AVIC Financial's stock will be delisted on May 27, 2025 [16] - Jingwang Electronics' major shareholders plan to reduce their holdings by up to 2.99% [17] Group 5 - Huaren Health intends to acquire stakes in three pharmaceutical chain companies for a total of 327 million yuan [18] - Huanrui Century's original shareholders are required to compensate for unfulfilled performance commitments with 116 million shares [20] - Tefa Service's shareholders plan to reduce their holdings by up to 3% [21] Group 6 - Maipu Medical is planning to acquire at least 51% of Easy Medical's equity, which will constitute a major asset restructuring [22] - *ST Jinshi will have its delisting risk warning lifted and its stock will resume trading on May 23, 2025 [22] - Guoke Micro is planning a major asset restructuring and will suspend trading [23] Group 7 - Defu Technology intends to acquire 100% equity of an overseas electronic circuit copper foil company [24] - Xince Standard's shareholder plans to reduce its holdings by up to 1% [25] - Xiouqiang Co. plans to reduce its holdings by up to 3% [27]

Key Points - Vanke A has signed a supplementary agreement with Shenzhen Metro Group for a loan of up to 4.2 billion yuan, with a pledge of up to 6 billion yuan in shares of its subsidiary, Wanwu Cloud [3] - Heng Rui Pharmaceutical has set the final price for its H-share issuance at 44.05 HKD per share, with plans to list on the Hong Kong Stock Exchange on May 23, 2025 [4] - Wan Dong Medical has elected Ma Chibing as the new chairman after Hu Ziqiang resigned from the position [5] - Tianqi Mould has confirmed that there are no undisclosed significant matters amid ongoing major asset restructuring [6] - Zhejiang Rongtai plans to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - ST Mingcheng intends to publicly transfer 45% of its subsidiary, Time Media, which will no longer be included in the consolidated financial statements [8] - Shanghai Xiba plans to purchase patent assets for 2 million yuan and 500,000 yuan, and establish subsidiaries to promote the commercialization of new technologies [9] - Jushen Co. has received a total of 95.7 million yuan in dividends from its six wholly-owned subsidiaries [10] - ST Asia Pacific has confirmed no undisclosed significant matters or ongoing major plans [11] - Tianrong Tianyu's controlling shareholder's agreement will not be renewed after its expiration [12] - Wangzi New Materials has stated that its energy storage capacitor business is minimal and will not significantly impact its performance [13] - Nanjing Port has clarified that its foreign trade container business does not have direct routes to the U.S. [14] - Jinlongyu has indicated that its solid-state battery business has not yet formed stable long-term revenue [15] - Tianzhihang's subsidiary plans to raise capital by introducing investors [16] - State Grid Information plans to acquire 100% of Yili Technology for 1.853 billion yuan, enhancing its revenue and profit [17] - ST Nongsang will remove its delisting risk warning starting May 23 [18] - Yipin Hong has stated that its innovative drug AR882 has not yet been launched and will not significantly impact recent performance [19] - Huanrui Century has announced a performance compensation plan requiring original shareholders to compensate 116 million shares [20] - Huaren Health plans to acquire stakes in three pharmaceutical chain companies for a total of 3.282 billion yuan [21][22] - Hongming Co. is planning to acquire 83% of Shenzhen Chisu for 1.51 billion yuan [23] - Aishida intends to acquire an additional 7% stake in its subsidiary Qianjiang Robot for 13.09 million yuan [24] - Dasheng Intelligent has signed a contract worth 11.5 million yuan for a high-efficiency machine room project [25] - Jinggu Co. has received a notice to supply wheels for a major global automaker, with expected sales of approximately 158 million USD over ten years [26] - Pingzhi Information has signed a framework agreement with China Mobile for antenna products worth up to 13.01 million yuan [27] - Shanghai Laishi's controlling shareholder plans to increase its stake by 250 million to 500 million yuan [28] - Qixia Construction's shareholder plans to reduce its stake by up to 3% [29] - Sichuan Gold's major shareholders plan to reduce their stakes by up to 5.5% [30] - Qingyun Technology's shareholders plan to reduce their stakes by up to 4.5% [31] - Rhein Biological's directors plan to reduce their stakes by up to 0.14% [32] - Qingmu Technology's shareholder plans to reduce its stake by up to 3% [33] - Sanrenxing's employee shareholding platform plans to reduce its stake by up to 3% [34][35] - Juzhi Technology's director plans to reduce his stake by up to 40,000 shares [36] - Jingwang Electronics' major shareholders plan to reduce their stakes by up to 2.99% [37] - Jujiao Co. plans to reduce its stake by up to 2.6% [38] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% [39]

莱茵生物（002166）公告，公司董事长、总经理谢永富，董事、副总经理白昱，董事、副总经理兼财务 总监郑辉，副总经理兼董事会秘书罗华阳因个人资金需求，计划自公告披露之日起15个交易日后的3个 月内，通过集中竞价方式减持公司股份合计101.85万股，占公司总股本的0.14%。减持价格将按市场价 格确定。 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-036 桂林莱茵生物科技股份有限公司 关于公司部分董事、高级管理人员减持股份的预披露公告 公司董事长、总经理谢永富先生，董事、副总经理白昱先生，董事、副总经 理兼财务总监郑辉女士，副总经理兼董事会秘书罗华阳先生保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示：桂林莱茵生物科技股份有限公司（以下简称"公司"）董事长、 总经理谢永富先生，董事、副总经理白昱先生，董事、副总经理兼财务总监郑辉 女士，副总经理兼董事会秘书罗华阳先生（以下简称"上述人员"）合计持有公 司股份 4,074,000 股，占公司总股本的 0.56%（总股本系扣除公司回购专用证券 账户上已回购股份后的数量，下同），上述人员计划自本公告披露之日起 15 个 交易日后的 3 个月内以集中竞价方式减持本公司股份合计 1,018,500 股（占本公 司总股本比例 0.14%）。 公司于近日收到董事长、总经理谢永富先生，董事、副总经理白昱先生，董 事、 ...